ClaireLKeatingMD

Critical Care Medicine, Cystic Fibrosis

Associate Professor of Medicine and Associate Director of the Gunnar Esiason Adult Cystic Fibrosis and Lung Program at Columbia University Medical Center

Request Appointment

Overview of Dr. Keating

Dr. Claire Keating is a pulmonologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Tufts University School of Medicine and has been in practice 14 years. Dr. Keating accepts several types of health insurance, listed below. She is one of 238 doctors at New York-Presbyterian Hospital and one of 97 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Pulmonology. She has more than 20 publications and over 500 citings.

Office
622 W 168th St
Ph 8-101
New York, NY 10032
Book by Phone+1(502) 309-2159

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pulmonary Disease and Critical Care Medicine, 2006 - 2009
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Tufts University School of MedicineClass of 2003
Cornell University, College of Agriculture and Life SciencesB.S. with Honors, Biological Sciences, 1997

Certifications & Licensure

NY State Medical License 2005 - 2026
NJ State Medical License 2021 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

OneCF Learning and Leadership Collaborative 2 Award Cystic Fibrosis Foundation, Team Leader, 2015
Adult Quality Improvement 3 Learning and Leadership Collaborative Award Cystic Fibrosis Foundation, Team Champion, 2013
Daniel M. Libby Program Director’s Award for Clinical Excellence Cornell Medical Center, 2006
Presidential Award for Citizenship and Public Service Tufts University, 2001
Honors in Biological Sciences Major Cornell University, 1997
Golden Key National Honor Society Cornell University, 1997
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Join now to see all

Clinical Trials

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation Start of enrollment: 2010 Oct 01
Completed
Phase 2
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) Start of enrollment: 2014 Mar 31
Completed
Phase 3
Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF) Start of enrollment: 2014 Aug 01
Completed
Phase 3
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor Start of enrollment: 2015 Jun 01
Completed
Phase 3
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation Start of enrollment: 2015 Aug 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

123 citations
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation
Uma Narayanasami, Rajani Kanteti, Julie Morelli, Alanna Klekar, Asma Al-Olama
Blood. 2001-10-01
16 citations
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Ahmet Z Uluer, Gordon MacGregor, Pilar Azevedo, Veronica Indihar, Claire Keating
The Lancet. Respiratory Medicine. 2023-06-01
17 citations
Cystic fibrosis is associated with an increased risk of Barrett's esophagus.
Rita M. Knotts, Quinn S. Solfisburg, Claire Keating, Emily DiMango, Charles J. Lightdale
Journal of Cystic Fibrosis. 2019-05-01

Press Mentions

Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceSeptember 26th, 2024

Committees

Stakeholder Advisory Board Member, NYC-Clinical Data Research Network 2014 - Present
Data Safety and Monitoring Board Member, Cystic Fibrosis Foundation Therapeutics, Inc. 2012 - Present
Publications and Presentations Committee Member, Cystic Fibrosis Foundation Therapeutic Drug Network 2012 - Present

Research History

Co-Principal InvestigatorCystic Fibrosis Foundation (C079-TDC09Y), Columbia University Therapeutics Development Network2010 - Present

Professional Memberships

American Thoracic Society - ATS
Member
American College of Chest Physicians - ACCP
Member

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment